Related Experiment Video
Updated: Aug 19, 2026
Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
Published on: March 2, 2014
Influence of recombinant human interleukin (IL)-7 on disease progression in mice infected with Friend virus complex
1Department of Medicine (Hematology/Oncology), Indiana University School of Medicine, Indianapolis 46202-5121.
Abstract:
Recombinant human (rhu) IL-7 was evaluated for its influence on disease progression in mice infected with the polycythemia-inducing strain of the Friend virus complex (FVC). DBA/2 mice were injected i.v. with FVC, and then treated s.c. with rhuIL-7. IL-7 significantly prolonged survival time and decreased spleen focus-forming virus (SFFV) levels, expression of SFFV mRNA and SFFV protein production in FVC-infected mice. IL-7 did not appear to directly inactivate SFFV. Although both splenic weight and cellularity in FVC-infected mice treated with IL-7 were higher than those of normal mice, they were respectively 58% and 66% lower than those of the untreated FVC-infected mice. NK-cell activity was substantially lower in FVC-infected mice than in normal mice, while IL-7 restored NK-cell activity to normal levels. IL-6 and IFN-gamma levels were markedly reduced in FVC-infected mice compared to normal mice, but treatment of FVC-infected mice with IL-7 restored these cytokine levels. While the actual mechanisms of these effects are not yet known, the results suggest the potential therapeutic efficacy of IL-7 for certain hematopoietic and viral disorders, possibly mediated through an action on accessory cells and cytokine production.
Insights
Recombinant human interleukin-7 (IL-7) therapy improved survival and reduced viral load in mice infected with Friend virus complex (FVC). IL-7 also restored immune cell activity and cytokine levels, suggesting therapeutic potential.
Area of Science:
- Immunology
- Virology
- Hematology
Background:
- Friend virus complex (FVC) infection leads to disease progression and immune suppression in mice.
- Interleukin-7 (IL-7) is a cytokine involved in lymphocyte development and immune regulation.
Purpose of the Study:
- To investigate the therapeutic potential of recombinant human IL-7 (rhuIL-7) in FVC-infected mice.
- To evaluate the effects of rhuIL-7 on disease progression, viral load, and immune responses.
Main Methods:
- DBA/2 mice were infected with FVC and subsequently treated with rhuIL-7.
- Survival time, spleen focus-forming virus (SFFV) levels, splenic cellularity, NK-cell activity, and cytokine levels (IL-6, IFN-gamma) were assessed.
Main Results:
- rhuIL-7 treatment significantly prolonged survival and reduced SFFV levels, mRNA, and protein production.
- IL-7 treatment did not directly inactivate SFFV but modulated splenic cellularity and restored NK-cell activity.
- IL-7 therapy normalized reduced levels of IL-6 and IFN-gamma in FVC-infected mice.
Conclusions:
- Recombinant human IL-7 demonstrates therapeutic efficacy in mitigating FVC-induced disease progression in mice.
- The therapeutic effects of IL-7 may involve modulation of accessory cells and restoration of key cytokine levels.
- IL-7 shows potential for treating certain hematopoietic and viral disorders.
